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Abstract - The introduction of fixed combination of 
ACEi+CCB (Fixed) has significantly increased patients 
compliance and adherence to therapy. At the moment, 
however, there are no data suggesting the better control of 
once-daily fixed (Fixed) over free doses in separate 
administrations combination therapy in hypertensives.  
In a population of 39 consecutive outpatient patients 
referred to the departmental Hypertension clinic of the 
University Hospital of Salerno Medical School with the 
first diagnosis of arterial hypertension, we tested the 
hypothesis that the Fixed achieve a better control of blood 
pressure than the Free combination.  Patients were 
randomized to either strategy and after 3 months patients 
underwent a clinical assessment to evaluate the 
antihypertensive effect. The two groups, matched for 
anthropometric and clinical parameters, received 
Amlodipine (5-10 mg/daily) and Perindopril (5-10 
mg/daily). Perindopril and Amlodipine doses did not 
significantly differ between the two groups. After 3 
months BP control was improved in both groups and BP 
targets were similarly reached in both groups (SBP; Fixed: 
61.54%; Free 69.23%; n.s. DPB; Fixed: 80.77%; Free 
84.62%; n.s.). The reduction in systolic blood pressure 
was similar in both groups (Fixed:7.64±2.49%; Free: 
7.81±4.00%, n.s.), while the reduction of diastolic blood 
pressure was greater in the Fixed group (Fixed: 
14.22±2.03%; Free: 4.92±5.00%, p<0.05).  
Although both strategies are effective in reducing BP, the 
use of Fixed dose has an advantage in the reduction of BP. 
The present study does not allow to identify the 
mechanisms of this difference, which can be assumed to 
be due to the pharmacokinetics of the drugs administered 
in once-daily fixed combination. 
Key words: Hypertension; combination therapy; ACE 
Inhibitors; Calcium Antagonist; Blood pressure 
control. 
 
I.  INTRODUCTION 
Hypertension is a global public health problem  
and its treatment is primarily aimed to reduce 
associated cardiovascular morbidity and mortality. 
Many observational studies show that hypertension 
control is still largely insufficient1 and recent studies have 
shown that only 20-30% of patients in drug treatment 
reaches the recommended pressure values in Europe2-4, 
emphasizing the importance of developing novel 
strategies for the management of this condition.  
Blood pressure control involves changes in lifestyle, 
including caloric intake restriction, exercise and smoke 
cessation, but in most cases the final strategy is 
pharmacotherapy.  
The pharmacological approach aims at reducing BP levels 
through an action on the peripheral resistance, cardiac 
output, or both factors. The choice for the initial therapy 
is from one of five classes of antihypertensive drugs, 
including diuretics (thiazides, chlorthalidone, and 
indapamide), beta blockers, calcium channel blockers 
(CCB), angiotensin-converting enzyme inhibitors (ACEi) 
and angiotensin II receptor antagonists (ARBs), either 
alone or in combination. Since there are no certain data to 
demonstrate the real superiority of a class of drugs over 
the others5-7, the choice of drugs should be individualized 
to each patient and may be influenced by the possibility of 
side effects, efficacy, safety, and by results of randomized 
controlled trials in specific populations of patients with 
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arterial hypertension8. 
Per ESH/ESC 2013 hypertension guidelines, regardless 
of the drug used, the monotherapy reduces the BP only 
in a limited number of hypertensive patients9. Therefore, 
the majority of patients requires the combination of at 
least two drugs to achieve BP control9. A recent meta-
analysis of 42 studies has demonstrated that the 
combination therapy reduces the blood pressure values 
much more than the use of a single drug in double 
dose10. The synergistic effect of dual combination 
therapy provides not only the hypotensive activity but 
also a better prevention of therapy complications. The 
concurrent use of drugs with different mechanisms of 
action can offset the potential adverse effects of each 
compound. The combination of drugs of complementary 
classes increases effectiveness in reducing BP about 5 
more than the simple increase in the dose of a drug10. 
Adherence to treatment in the long term is necessary to 
BP control, and combination regimens can facilitate both 
the reduction of the number of drugs and the frequency 
of dosing required; in this regard, a recent study has 
found that adherence was inversely proportional to the 
number of prescribed drugs11.  
Among the combination therapies which may be 
employed in treatment of BP, we must choose the most 
efficient combinations to reduce the global 
cardiovascular risk profile and increase safety and 
tolerability. The use of a strategy based on the 
combination of drugs which antagonize the renin-
angiotensin system is able to significantly reduce the 
risk of major cardiovascular events12 and 
discontinuation of therapy13. The Accomplish study14 
found a significant superiority of the ACEi associated 
with a CCB compared to the association ACEi/diuretic. 
The combination amlodipine-perindopril has been 
widely used in the ASCOT study, being more effective 
in lowering blood pressure (BP) and cardiovascular 
events than the combination of a beta-blocker with a 
thiazide15. Moreover, through their sympatholytic 
effects, ACEi attenuate the increase in heart rate that can 
occur during treatment with a dihydropyridine CCB. In 
addition, ACEi reduces the peripheral edema, which is a 
limiting side effect of calcium channel blockers16, so the 
ACEi+CCB combination is particularly recommended9. 
In this regard, the fixed combination ACEi/ARB + CCB 
appears particularly promising as it can significantly 
reduce BP, improve the cardiovascular outcome, prevent 
organ damage, improve adherence to therapy. The use 
of the combination of two antihypertensive drugs at 
fixed doses in a single tablet reduces the number of pills 
that must be taken daily, with a better compliance to 
therapy17. Single-pill combinations are now widely 
available because at low doses fixed dose combinations 
may have greater efficacy and better tolerability than 
monotherapy18. 
Nevertheless, it is not clear whether the fixed dose 
therapy presents any advantage on BP control 
compared with free dose combination therapy. In this 
regard, the aim of our study was to assess whether the 
use of fixed-dose (ACEi+ CCB) produces better control 
of BP in hypertensive patients compared with the free 
dose. 
 
II.  MATERIALS AND METHODS 
A. Study Population 
Our study included 39 patients referred to the 
Hypertension Clinic of Salerno Medical School Hospital 
in Salerno, with the first diagnosis of arterial hypertension 
and in the absence of a previous treatment. At the time of 
enrollment visit, patients signed a consent to anonymous 
participation, in compliance with the regulations of good 
clinical practice and privacy. Study participants were 18-
75 years old with essential hypertension (defined 
according to the ESH / ESC 2013 guidelines). Patients 
were excluded if they had secondary hypertension, 
malignant hypertension, CRF (chronic renal failure), 
oncological conditions  or cirrhosis. Patients were also 
excluded if they had medical and surgical disorders that 
alter absorption, distribution, metabolism and excretion of 
drug treatment. The study protocol was approved by the 
competent University Hospital Ethical Committee. 
 
 
B. Study Design 
Patients were randomized to either fixed dose or free 
dose combination therapy, with Perindopril (5 or 10 mg) 
and Amlodipine (5 or 10 mg) with a 2:1 randomization 
design based on a power analysis. Doses were decided 
according to anthropometric, clinical, biochemical and 
instrumental doses by experienced medical staff. The 
Fixed group received one single tablet containing 
Perindopril/Amlodipine at the appropriate dose. The Free 
group, received Perindopril and Amlodipine in separate 
tablets at the appropriate dose. Groups were matched for 
age, sex, BMI, systolic BP (SBP) and diastolic BP (DBP). 
At baseline and at follow-up we evaluated clinical 
(weight, height, BMI, heart rate, BP) and biochemical 
parameters (blood glucose, serum cholesterol, LDL, HDL, 
triglycerides, blood urea nitrogen, creatinine, creatinine 




C. Clinical parameters 
In accordance with the ESH guidelines9, BP 
assessment was carried out noting two measurements in 
the supine, in sitting and in standing position, spaced apart 
from 1-2 minutes. For the current study mean values in 
sitting position were considered. BP measurements were 
assessed by trained personnel using a dedicated, upper 
arm, electronic machine (Afib screen, Microlife, Italy). 
 
 
D. Anthropometric parameters 
The weight classes were defined by BMI 
[weight(kg)/height (m)2]. In adults, overweight is 
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E. Biochemical parameters 
For each patient, the following laboratory tests were 
evaluated: fasting glucose, total cholesterol, LDL, HDL, 
triglycerides, blood urea nitrogen (BUN), serum 
creatinine and creatinine clearance (calculated with 
MDRD or Cockroft formula). 
Fasting blood glucose greater than 126 mg/dl was used for 
screening for diabetes.  
 
 
F. Follow-up with computerized medical records 
The patient population was included in a central 
database that uses Wincare software (TSD-Projects, 
Milan, Italy), which contains separate electronic sheets for 
medical history, physical examination, laboratory tests, 
electrocardiogram, cardiac ultrasounds, other imaging 
tests and ambulatory blood pressure monitoring. The data 
was updated at each follow-up visit with a revaluation 
deadline set at three months. The data of each patient are 
stored on the hospital server and protected by a firewall 




All patients were subjected to one-dimensional 
echocardiography (M-mode), two-dimensional (B-
mode) and Doppler function via the 5-1MHz probe (E9, 
GE Healthcare).  
 
 
H. Statistical analysis 
Categorical data are presented as percent while 
continuous data are indicated as means ± standard error. 
The quantitative analysis was performed using T-test for 
unpaired data or ANOVA as appropriate, while the 
qualitative analysis was performed using non-parametric 
tests (χ2 test). A value of p-value <0.05 was considered 
statistically significant. All data were analyzed using 
Prism 6.0 (GraphPad Software, Inc., San Diego, CA). 
 
 
III.  RESULTS 
A. Patient disposition and baseline characteristics  
We considered 39 patients with hypertension, aged 
between 35 and 70 years, with a recent diagnosis of 
hypertension and initiated to treatment with 
Perindopril/Amlodipine. Patients were randomized to 
fixed-dose (Fixed, n=26) or to free dose (Free, n=13) 
combination therapy. 
The anthropometric parameters of the two groups are 
similar (Table l), and the two groups did not differ as 
regards to biochemical and metabolic parameters, 
kidney damage (Table 2), and cardiac damage (left 
ventricular mass index: Fixed: 139.80±8.48 vs Free: 
136.14±9.28g/m2, n.s.). Patients were not diabetic, while 
13 Fixed vs 9 Free patients take antilypidemic therapy. 
 
 





AGE (years) 61.79±2.28  64.23 ±2.45  n.s. 
WOMEN (%) 31 31 n.s. 
BMI (Kg/m2) 29.68±1.39  29.73±1.10  n.s. 
HEIGHT (cm) 167.12±2.09  165.77±2.00  n.s. 
WEIGHT (Kg) 82.38±3.59 81.85±3.86 n.s. 
 
Table 1. Anthropometric parameters of the study participants. Data are 

















168±32 182±48 n.s. 
LDL(mg/dl) 91±28 106.3±45 n.s. 
HDL(mg/dl) 52±18 46±10 n.s. 
TRIGLYCERIDES
(mg/dl) 
119±40 131±44 n.s. 
BUN (mg/dl) 41±7 44±9 n.s. 
CREATININE 
(mg/dl) 
0.87±0.17 0.88±0.17 n.s. 
CREATININE CL 
(ml/min) 
100±46 92±21 n.s. 
 
Table 2. Biochemical parameters of the study participants. Data are 




Basal values of BP were overlapping between the two 
groups, with an average value of SBP and DBP, 
respectively, of 155.00±4.34 mmHg and 92.27±2.94 
mmHg in the fixed-dose group, and of 151.54±5.75 
mmHg and 85.85±2.83 mmHg in free dose group. 
Perindopril and Amlodipine doses did not significantly 
differ between the two groups, although patients with a 
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fixed dose received a lower albeit not significant dosage 
of Perindopril (Fixed= Perindopril 8.85±0.44 mg, 
Amlodipine 7.12±0.50 mg vs Free= Perindopril 
10.50±1.68 mg, Amlodipine 7.50±0.80 mg; n.s.). 
 
B. Comparison of BP after treatment 
Three months after the beginning of the treatment, the 
percent of patients that achieved good control (<140/90 
mmHg) of BP was similar between the fixed and free 
combination groups, both for SBP (Fixed: 61.54 vs Free: 
69.23%; n.s.) and DPB (Fixed: 80.77 vs Free: 84.62%; 
n.s.). Furthermore, the reduction of SBP was observed in 
both groups (Figure 1).  
 
 
Figure 1. Effects of once-daily fixed dose vs free dose combination 
therapy on systolic blood pressure (SBP). Fixed group (Left graph) 
showed a statistically significant reduction of SBP, while the reduction 
of Free group (Right graph) was not significant. Statistic significance 




Similarly, DBP values were improved (Fixed: 78.35±2.17 
mmHg; Free: 80.62±2.90 mmHg) (Figure 2). To evaluate 
the amplitude of effectiveness of treatment, we assessed 
the delta of BP, that is the ratio between the values of BP 
at the end of the treatment over those registered at 
baseline. The reduction in systolic blood pressure showed 
no major differences between the two groups (Fixed: 
7.64±2.49 vs Free: 7.81±4.00%, n.s.), while the reduction 
in diastolic blood pressure (Figure 2) was significantly 
larger in the Fixed group (Figure 3).  
 
Figure 2. Effects of once-daily fixed dose vs free dose combination 
therapy on diastolic blood pressure (DBP). Fixed group (Left graph) 
showed a statistically significant reduction of DBP, while the reduction 
of Free group (Right graph) was not significant. Statistic significance 
was assessed by T-test (*= p<0.05; FU= follow-up). 
 
Figure 3. Differences between fixed dose vs free dose combination 
therapy on blood pressure reduction. The reduction in systolic blood 
pressure (SBP) (Left graph) showed no major differences between the 
two groups, while the reduction of diastolic blood pressure (DBP) (Right 
graph) was significantly higher. Statistic significance was assessed by T-
test (*= p<0.05). 
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IV.  DISCUSSION 
The results of this study demonstrate for the first 
time that the fixed combination therapy of ACEi/CCB 
exerts better antihypertensive response than the free 
dose combination therapy of the same two drugs. Our 
results indicate that this effect is particularly true for 
diastolic blood pressure, more than for SBP. We did not 
investigate the underlying mechanism, which can be 
related to the pharmacokinetics and pharmacodynamics 
involved in the administration of the drugs and how 
they are affected by administration modality. 
In this regard, it was reported that the pharmacokinetic 
profile of an ACE inhibitor/ARB is not affected by co-
administration of a calcium channel blocker, showing 
that the peak occurs after less than four hours, during 
both the monotherapy and the combination with a 
calcium antagonist19. On the contrary, the peak plasma 
concentration in chronic treatment with calcium 
antagonist was reached after 8 hours when administered 
alone or in combination with olmesartan19. This 
observation rules out any significant pharmacokinetic 
interaction between ACE-inhibitor/CCB which could 
lead to the reduction of the antihypertensive cumulative 
or adverse side effects19 and suggests that the 
pharmacokinetics interferes less with the treatment 
compared to pharmacodynamic.  
Another possible mechanism that can be considered to 
explain the result is compliance and adherence to 
therapy. In our study, we assessed the adherence to 
therapy by interviews at the time of visit. All patients 
referred to be adherent to treatment, a statement that in 
our study design could not be verified. A poor adherence 
to treatment or a delay in the assumption of the second 
pill can both explain the difference in terms of BP 
reduction observed between our two populations.  
Treatment compliance, adherence, and persistence are 
key factors to achieve and maintain BP control, reduce 
mortality and improve the quality of life20, and reduce 
health care costs21. In fact, poor adherence not only 
implies an increase in cardiovascular mortality but also 
the increase of social and individual costs. Obstacles to 
adherence to treatment include tolerability, the number 
of drugs and the complexity of the drug regimen22, 23. In 
fact, increasing the dose of a single antihypertensive 
drug in an attempt to achieve an adequate 
pharmacological response can lead to an increase in side 
effects, resulting in the reduction of compliance and 
failure to achieve blood pressure goals. The combination 
therapy using two or more drugs with different and 
complementary action mechanisms offers the 
opportunity to improve control of blood pressure and, 
using the lowest drug doses, reduce the risk of side 
effects24. Our results indicate that, indeed, fixed therapy 
obtains even larger BP reduction using tendentially 
lower doses of the drugs.  
Recent guidelines recommend the use of combination 
therapy as an alternative to monotherapy as initial 
treatment, in particular in patients at high cardiovascular 
risk25. In this regard, it was observed a significant 
increase in compliance and persistence to combination 
therapy administered once, in line with the results of a 
recent meta-analysis that evaluated the use of 
combination therapies administered once for various 
chronic diseases, such as diabetes mellitus, 
hypertension, and HIV17. Finally, it is observed a 
reduction of 20% of adverse events associated with the 
use of combination therapy administered once26, 27. 
Adverse events associated with the use of two-drug 
combinations were lower than those of the two drugs 
given separately28. However, the use of ACE/ARB+
CCB administered once in the treatment of hypertension 
is still not widespread, although hypertensive patients 
often have a complex treatment regimen, associated with 
a poor compliance29. For what concern social costs, 
most of the times the cost of the most used combination 
for hypertension administered once30 are lower than the 
individual drugs. In addition, abundant data demonstrate 
a clear inverse relationship between increased 
compliance with treatment and health care costs31 . 
Our results show an incredibly high level of BP control 
in naïve patients. Indeed, it is estimated that less than % 
of hypertensive patients in active treatment achieves BP 
control. Our results show BP control in almost 70% of 
patients after 3 months of treatment.  Contributing to 
this result are the short duration of follow-up (3 months) 
and the use of a telematic follow-up, that has proven to 
be able to improve the compliance to treatment in 
previous studies32. The use of both a management 
strategy of the hypertension therapy and an appropriate 
drug regimen might help to achieve in real life a rapid 
control of BP. This is an important advantage, as it 
produces a more effective control of the cardiovascular 
risk, especially in hypertensive patients with multiple 
conditions, (diabetes, cerebrovascular, cardiovascular or 
renal disease), that more frequently require multiple 
therapies. According to the ESH/ESC 2013 guidelines, 
combination therapy must be considered the initial 
treatment step in these patients. Our result justifies the 
use of fixed dose to achieve a larger control of BP.  
In conclusion, although both fixed and free dose 
ACEi/CCB combination therapy are effective in 
reducing BP, the fixed doses in a single tablet has a 
particular advantage in the reduction of BP. This 
advantage must be taken into account in the choice of 
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